Is it ethical to prevent secondary use of stored biological samples and data derived from consenting research participants? The case of Malawi by Randy G. Mungwira et al.
DEBATE Open Access
Is it ethical to prevent secondary use of
stored biological samples and data derived
from consenting research participants?
The case of Malawi
Randy G. Mungwira1, Wongani Nyangulu1, James Misiri1, Steven Iphani1, Ruby Ng’ong’ola1,
Chawanangwa M. Chirambo1, Francis Masiye2,3 and Joseph Mfutso-Bengo3*
Abstract
Background: This paper discusses the contentious issue of reuse of stored biological samples and data obtained
from research participants in past clinical research to answer future ethical and scientifically valid research
questions. Many countries have regulations and guidelines that guide the use and exportation of stored biological
samples and data. However, there are variations in regulations and guidelines governing the reuse of stored
biological samples and data in Sub-Saharan Africa including Malawi.
Discussion: The current research ethics regulations and guidelines in Malawi do not allow indefinite storage and
reuse of biological samples and data for future unspecified research. This comes even though the country has
managed to answer pertinent research questions using stored biological samples and data. We acknowledge the
limited technical expertise and equipment unavailable in Malawi that necessitates exportation of biological samples
and data and the genuine concern raised by the regulatory authorities about the possible exploitation of biological
samples and data by researchers. We also acknowledge that Malawi does not have bio-banks for storing biological
samples and data for future research purposes. This creates room for possible exploitation of biological samples and
data collected from research participants in primary research projects in Malawi. However, research ethics
committees require completion and approval of material transfer agreements and data transfer agreements for
biological samples and data collected for research purposes respectively and this requirement may partly address
the concern raised by the regulatory authorities. Our concern though is that there is no such requirement for
biological samples and data collected from patients for clinical or diagnostic purposes.
Summary: In conclusion, we propose developing a medical data and material transfer agreement for biological
samples and data collected from patients for clinical or diagnostic purposes in both public and private health
facilities that may end up in research centers outside Malawi. We also propose revision of the current research
ethics regulations and guidelines in Malawi in order to allow secondary use of biological samples and data
collected from primary research projects as a way of maximizing the use of collected samples and data. Finally, we
call for consultation of all stakeholders within the Malawi research community when regulatory authorities are
developing policies that govern research in Malawi.
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Background
Clinical research may sometimes involve exportation
and importation of biological samples and data which
serve as the back bone of viable scientific or biomedical
research. As emerging innovations in the fields of genetics,
genomics and biotechnology increase, the value of
biological samples and data [1, 2] creates greater demand
that will lead to increased exportation of biological samples
and data for technologically advanced biomedical research
mostly in developed countries. One of the initiatives in
this area is the H3Africa, an international collaboration
of scientists which seeks to foster genetic and genomic
research on diseases that are pertinent to African people
with the goal of improving the health of African popula-
tions [3]. Most developed countries and some develop-
ing countries have regulations and guidelines that guide
the use and exportation of stored biological samples and
data in future research. However, Malawian research
ethics regulations and guidelines do not allow storage
and secondary use of biological samples and data in
future unspecified research [4, 5]. Therefore, the aim of
this paper is to address the current debate in Malawi
regarding storage, use and exportation of biological
samples and data and make recommendations that will
protect research participants and benefit the biomedical
research community in the country.
Collection and storage of biological samples and
data in the developed world
In the United States of America (US), it is allowed to
collect and store biological samples and data for future
research. However, there are disagreements on the issue
of informed consent. According to the US federal regula-
tions “also known as the Common rule” or the Code of
Federal Regulations (CFR), research on stored biological
samples and data is explicitly exempt from review by
institutional review boards (IRB) [1]. This is on condi-
tion that sources cannot be “identified directly or
through identifiers linked to the samples and data” [1].
Some investigators have interpreted this to mean that
there is no need for informed consent so long as the
biological samples and data are “anonymized” and
delinked from the sources [1]. In fact, the American
Society of Human Genetics (ASHG) is of the view that
re-consenting individuals for research with “stored
samples and data that poses only minimal risk” is not
necessary [1]. Other commentators recommend a check-
list of options to allow research participants during the
consent process to approve or refuse different types of
research [2]. This is what is referred to as multi-layered
or tiered consent. The National Bioethics Advisory
Commission (NBAC) in the US recommends this
model of consent and specifically includes six separate
choices to be provided while the National Action Plan
on Breast Cancer recommends research participants to
be allowed to approve research on the disease being
studied and separately approve or refuse research on
other diseases in what is known as broad consent [2].
In Europe, most scientists are of the view that broad
consent is acceptable for biological samples and data
to be used for research that was not part of the original
research protocol [6].
It is important to note that these guidelines are not
based on empirical research done on research partici-
pants but mostly on the interpretation held by the dif-
ferent bodies on the principle of respect for persons or
autonomy and informed consent [1]. A study done in
the US (n = 504) found that for biological samples and
data derived from research, the majority of research par-
ticipants would not require their consent for identifiable
samples and data and even less than 12.1 % of the research
participants would require consent for anonymized
samples [1]. For clinically derived samples and data, the
majority of participants (65.8 %) would require their con-
sent for identifiable samples and data while fewer (27.3 %)
would require consent for anonymized samples and data
[1]. This suggests that “consent should be required for
research using clinically derived, identifiable samples and
data, but waived for additional research using research-
derived, anonymized samples” [1]. Of note, these find-
ings may not be generalisable as this study involved
mostly elderly female Caucasian respondents with
high educational levels and income [1].
Collection and storage of biological samples and
data in Sub-Saharan Africa
Most countries in Sub-Saharan Africa require researchers
from both academic and research institutions to complete
material transfer agreement forms (MTAs) before
shipping biological samples and data collected from re-
search participants to academic or research institutions
overseas, and mostly to developed countries. In the MTA
forms, the researchers are required to justify importation
and exportation of biological samples and data to the
institutions in the developed countries where the samples
and data are sent for further analyses and tests [15].
Though collected from research participants by re-
searchers in the academic and research institutions,
samples are considered as the property of governments
where the research participants who provide the sam-
ples come from and research ethics committees (RECs)
are mandated with the task of reviewing the MTAs on be-
half of their institutions. Some of the RECs are institutional
reviews boards (IRBs) based in the academic or research
institutions that send the samples and data while others are
government-owned RECs that belong to research units of
the Ministries of Health (MoH). These RECs are considered
as custodians of the samples/data and they are seen to
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represent the interests of research participants who provide
the samples/data. Today, completion of the MTA forms
has become standard practice and it is intended to discour-
age researchers in academic and research institutions from
shipping samples and data to institutions in developed
countries and to encourage them to develop local capacity
and expertise to perform all tests and analyses of samples
and data in institutional labs in the developing countries.
The completed MTAs have to be reviewed and approved
by REC members before the samples and data are exported.
The MTAs are one feasible and fair mechanism to prevent
abuse and exploitation of human samples and data for
clinical research while promoting autonomy of research
participants through informed consent. Most MTAs
address the following issues [11]:
 Intention for collecting the sample/data.
 Justification for requiring a biological sample/data.
 Duration for storage of the sample/data and its
justification.
 The place where the sample/data will be kept.
 Ownership
 Control of the sample/data.
 Access
However, there are variations in regulations governing
use of biological samples and data in Sub-Saharan Africa.
The National Health Act of 2003 of South Africa requires
that research participants must provide informed consent
before donating biological samples and data but the Act
does not have guidelines on reuse of such samples and
data in research [7]. The Standard Operating Procedures
for Biomedical Research in Botswana require prospective
donors to be provided with the options to decide whether
their donation should be stored for future use and that the
Health Research and Development Committee (HRDC)
must approve any protocols that would reuse the tissue
samples and data [7]. The Gambian guidelines devel-
oped in 2001 do not require informed consent for
anonymized unlinked samples, but regulatory approval
of the government or the Ethics Committee is required
for the reuse of the anonymized samples and data [7].
However, the Gambian guidelines require researchers
to obtain informed consent from research participants
for all identifiable samples and data but this may be
waived by the Ethics Committee [6]. The Ugandan reg-
ulations require that a consent form be provided in
order to collect and store a biological sample, in
addition to providing information on storage, study
purpose, confidentiality and future use. In the Ugandan
case, research participants have the option of deciding
whether their samples are stored to be used in the
future or not [7]. In Zambia, the 2013 regulations state
that “biological material and data can only be collected
for the manner in which it was indicated in the research
protocol” [7] but the regulations do not allow secondary
use of biological samples and data. In Malawi, the research
ethics regulations and guidelines do not allow the use of
stored biological samples and data in future research [8].
The variations in national regulations and guidelines
reflect the differing perspectives of research participants
across several African countries. A study done in
Uganda (n = 343) found that 95 % of the research partic-
ipants would consent to reuse of samples and data with-
out additional consent as long as the Institutional
Review Board approved it [6]. Another study done in
Egypt (n = 600), 44.3 % of the participants felt consent
forms should include a separate section for storage and
future use of samples [7]. In a recent South African
study (n = 200), 77.5 % of the participants were comfort-
able with storage of samples while 12 % of the partici-
pants said they would require reasons for storage and
would want to give separate consent for storage [7]. In a
study conducted in Kenya by Langat, it was reported
that a large proportion of proposals submitted to ethics
committees requested the re-use of samples either in
archives or from previous research projects but half of
the consent forms of these protocols did not provide
information to potential research participants nor did
they request permission from research participants
about either storage or exportation of their samples
[16]. This diversity comes as no surprise as Africa is a
multicultural society and the views of one country may
not be indicative of the rest of the continent [7]. To
the best of our knowledge, there is no empirical study
conducted in Malawi that assessed the view of research
participants and community members with regards to
storage and future use of biological samples and data.
Benefit/risk assessment of current practices in
Malawi
Currently, research ethics committees in Malawi do not
allow storage and use of biological samples and data for fu-
ture unspecified research [4, 5]. The National Commission
for Science and Technology (NCST) in a document titled:
What is the National Regulatory Requirement and Position
on Accessing, Collection, Storage and use of Human
Biological Specimen for research in Malawi stipulates that
researchers are not allowed to collect biological specimens
and data that are not required to address the study objec-
tives; tests on biological specimens should only be as ap-
proved by the approved protocol and specimens collected
for a particular purpose should not be used for any other
purposes [4, 5]. The NCST document further states that it
is not allowed in Malawi to consent research participants to
collection, use and storage of specimens for future use in
research or other purposes [4, 5]. This stand has been
adopted and is being implemented by the local research
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ethics committees such as the National Health Sciences
Research Committee (NHSRC) and the College of
Medicine Research and Ethics Committee (COMREC) [9].
However, Malawi has benefited greatly from research
done on stored tissue, blood samples and data. In 2001,
Glynn et al. published the results of a study which
showed that HIV had been present in Karonga (northern
Malawi) as early as 1982 [12]. The samples and data that
were used had been collected for a different purpose in a
population survey dating back to 1981 [12]. Reuse of
these samples and data was authorized by the NHSRC.
Malawi like other developing countries has limited
capacity to conduct complex biomedical and genetic
tests required to answer scientific and ethically valid
questions. This has allowed researchers to obtain ethics
approval from local ethics committees to export
biological samples and data to countries where such
biomedical and genetic tests are available. However, the
regulatory authorities are concerned that these exported
biological samples and data may be subject to abuse and
exploitation by researchers. Indeed, international collab-
orative research has been subject to abuse and exploit-
ation in the past and not only on issues of stored
biological material [10]. There has been differential ex-
posure to risks among communities in developing coun-
tries as compared to their counterparts in the developed
world and lack of or unequal access to benefits as well
as potential profits from research [10]. This is expressed
in the views of some research participants with regard to
benefit sharing. In a South African study (n = 200), over
a third (39.5 %) of participants indicated that “they
would mind if researchers or research organizations gen-
erated profits from the research in which they were in-
volved” [7]. Of this group, 43 % would want a share of
the profits [7].
It should also be noted that while it is the duty of
government and RECs to promote the interests of the
research participants and prevent their exploitation,
such efforts may amount to unnecessary paternalism if
the affected research participants are not involved in
such decisions [10]. For examples, the restriction
placed on consenting research participants not to do-
nate biological samples and data for future research in
the NCST document can be interpreted to assume that
research participants in Malawi are not capable of de-
ciding on their own how biological samples and data
collected from them may be used. This would be
against the principle of autonomy or respect for
persons.
John Rawls, one of the contemporary philosophers once
stated that "justice as fairness serves as a basis of informed
and willing political agreement between citizens viewed as
free and equal persons “[13]. Thus, when justice is taken
for fairness, it is important to bear in mind that there are
many ways of being fair and being ethical. Hence, the
NCST seems to suggest that not allowing the secondary
use of biological samples and data is the only way to avoid
doing wrong and yet there are more important factors that
come prior to the collection of biological samples and data
that should matter most. Such factors include the respect
of autonomy through ensuring that informed consent is
obtained when collecting biological samples and data for
any future use. It would be fair to allow competent re-
search participants to make such decisions on their own
without being paternalistic.
Restrictions on secondary use of biological samples
and data imply that any tissue remaining at the comple-
tion of a particular study should either be kept in storage
indefinitely or be disposed of. This amounts to wastage
of valuable biological material that could be used to ad-
vance medical knowledge for better interventions and
such a restriction is not cost effective. This restriction
also subjects research participants to biological sample
and data recollection in order to carry out secondary
research. This exposes them to additional risk and con-
tradicts the principle of non-maleficence.
The restrictions set forth by Malawian regulations and
guidelines also run the risk of selective justice which is
another form of injustice. While being restrictive on bio-
logical samples and data derived from research, which is
heavily controlled and closely monitored by research
ethics committees, regulatory bodies are silent on sam-
ples and data derived from medical centers for clinical
diagnosis that could end up in research centers. There-
fore, we propose the introduction and utilization of a
separate material transfer agreement which shall be
called medical material transfer agreement (MMTA) for
exportation of biological samples and data that are col-
lected from patients in both private and public health
facilities for clinical purposes.
Both the National Health Sciences Research Committee
and COMREC do require completion and approval of
MTAs for biological samples and data collected in
research settings. However, there is no data and material
transfer agreement that is designed for biological samples
and data collected in clinical settings that may later on be
used for research purposes. This may create a gap for ex-
ploitation of biological samples and data collected for
diagnostic purposes. Although comprehensive, the MTA
in research settings does not address the issue of how
samples and data will be handled after research activities
are over. As such, there is still room for researchers to ex-
ploit biological samples and data collected for research
purposes. Creating a bio-bank or bio-repository center in
the country and requesting return of samples and data
after a specified period may be a viable alternative to bet-
ter regulate handling of human samples and data for
medical research.
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However, we are of the opinion that broad consent for
storage and future use of biological samples and data
done at the time of sample and data collection may be
the best model of consent to allow unspecified ethical
research that will be reviewed and approved by an ethics
committee [14]. By definition, broad consent is “consent
for an unspecified range of future research subject to on-
going research oversight [18]. By giving broad consent, a
research participant is deemed to have surrendered con-
trol of their biological sample and data and implicitly
agreed to use of the sample and data in future studies as
long as the studies are reviewed and approved by research
ethics committees and there is a possibility to withdraw
consent [3]. This means that individual research partici-
pants who provide broad consent are protected by research
oversight mechanisms which ensure that future proposed
research is ethical and poses no greater than minimal risk
to the research participants and the research participants
themselves have the right to withdraw their samples and
data. In addition, Grady and colleagues have reported
on empirical studies that have showed that individual
research participants who provide broad consent are
reassured that their interests will be protected when
oversight mechanisms are in place to review future
proposed research [18, 19]. Furthermore, in an analysis
of informed consent documents for 13 of the 19 H3
Africa projects done by Munung and others, they re-
ported that 8 of the H3 projects used broad consent
while 4 research projects used tiered consent and 1
used specific consent [20]. This means that broad con-
sent is still the most preferable model of consent used
in genetic and genomic studies in Africa. Hence, broad
consent may address the problem of giving consent for
future use of previously collected samples and data.
There are also other consent models which could be
used. A multi-layered/tiered consent is a consent model
in which research participants are given a set of options
which allow them to select how they want to participate
in the research. Multi-layered/tiered consent can used
where researchers want to give options to research
participants to choose whether they want their samples
and data to be used in future studies or not [21]. This
empowers research participants to consent to use of
their samples and data for a particular study and in se-
lected future related studies. However, tiered consent does
not allow researchers to use research participants’ samples
and data for research in which the research participants did
not consent to [21]. Finally, researchers can choose to ob-
tain specific consent from research participants in which
case the research participants will permit the use of their
biological samples and data just for the current study and
they will not allow any use of their samples and data in
future studies [1, 7]. Our understanding is that it is possible
to obtain ‘informed consent’ from research participants
using the three different models of consent we have
highlighted above as long as potential research partici-
pants are provided with adequate information, they have
understood that information and after considering the in-
formation, they have arrived at decisions to participate in
research or not without having been subjected to coer-
cion, undue influence, inducement or intimidation.
In circumstances where the research ethics committee
recommends re-consenting of research participants hav-
ing obtained specific consent in primary research projects,
researchers would then be obliged to do so but if it is not
feasible to re-contact research participants for consent to
use stored biological samples and data for other purposes,
the research ethics committee may provide a waiver or
may consent on behalf of the research participants. As
Nienaber puts it, “research in vulnerable populations is not
by definition exploitative and unethical” and “paternalistic
attitudes are denigrating” [10]. Therefore, measures taken
to safeguard research participants from exploitation need to
be reasonable, not very restrictive and should be respectable
of the population being protected. After all, as Tindana and
others have noted, “consent processes are a means of re-
specting research participants’ autonomy and decision-
making capacity as well as enabling them to choose to
avoid any potential harms of research by declining to take
part in research” [17]. As such, paternalistic tendencies to
safeguard exploitation of research participants are un-
reasonable and they do not respect the autonomy of
consenting research participants.
Recommendations
The current view held by the National Health Sciences
Research Committee and COMREC are restrictive and
may prove to be detrimental to health research in
Malawi. As such, there is need for review of the policy
stand at the national level. Research participants must
be allowed to give informed consent if they so wish or to
decline use of their biological samples and data derived
from them for any other purpose including in future
research. As an important component of medical
research, research participants’ autonomy should be
respected by allowing them to decide what they feel is
the best fate for their donated biological samples and
data. This could either be biological sample/data reuse
or destruction.
Research ethics committees and regulatory bodies
should continue doing vibrant reviews of medical research
and put in place measures to avoid research participants’
exploitation and abuse. To better address regulatory
bodies’ concern about exploitation of biological samples
and data by researchers, further empirical social science
research needs to be conducted locally to assess the views
of research participants and the public on collection,
storage and future reuse of biological samples and data
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and inform policy makers accordingly. There is also need
to educate the public about the benefits of future use of
biological samples and data.
We also recommend that government and local re-
search institutions should invest in developing infrastruc-
ture that will allow processing of biological samples and
data locally. In the absence of local capacity, it is unfair to
hinder exportation of biological samples and data for good
biomedical research. This would allow better regulation of
biological samples and data that are collected both for
medical research and diagnostic purposes.
There is also need to introduce a medical data and mater-
ial transfer agreement document for biological samples and
data derived in medical centers for clinical diagnostic pur-
poses that could end up in research centers. The current
policy is rigid and too strict on research derived samples
and data but there is no strict control on biological samples
and data derived from clinical investigations or procedures.
The current framework is also silent on proof of de-
struction of biological samples and data when the research
is over. Hence, we recommend the development of a local
bio-bank in Malawi where biological samples and data
should be returned after the agreed period of storage has
passed. Since establishing a bio-bank is likely to take time,
a remote site can keep the biological samples and data in
storage while allowing Malawian researchers the right to
access the biological samples and data.
Conclusions
As genetic, genomic and biomedical research technologies
become more advanced, biological samples and data col-
lected for specific research objectives may be of great
value to study other secondary outcomes. Where genetic
and genomic studies are involved, we are aware that
the National Health Sciences Research Committee is
mandated to review them. However, in both clinical
research and genetic/genomic studies, much emphasis
should be placed on collection, storage and obtaining
consent for future reuse of biological samples and data.
This has the potential to greatly benefit the nation and
the medical research community in Malawi. However,
this can only occur if the guidelines governing such
research are reasonable, fair and objective. It is there-
fore necessary to review existing guidelines and allow
secondary use of stored biological samples and data.
Asking research participants to donate a sample or
data for each research question when new research
questions could potentially be answered by already
existing samples and data is unnecessary duplication
and unfair. This underutilization of biological samples
and data constitutes reckless wastage of valuable and
scarce human biological samples and data. While we
acknowledge the genuine ethical concern by the National
Commission for Science and Technology that it is trying
to avoid exploitation of biological samples and data
collected in Malawi for research purposes, there is no em-
pirical evidence that researchers can exploit samples and
data they collect in primary research projects. In addition,
the current regulatory framework is punitive to those who
want to be efficient for other emerging research questions.
Too much restriction may also undermine training of
local researchers as most high technology research is cur-
rently conducted outside the country.
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